polo
11 articles
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
ASCO Annual Conference: Highlights in Pancreatic Cancer Research
Dr. Allyson Ocean reviews some of the latest pancreatic cancer research results, including new treatments for some patients.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
The Impact of BRCA Is Broader Than Breast and Ovarian Cancer
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
For Pancreatic Cancer Patients, Pain Control Through Targeted Radiotherapy
Dr. Yaacov Lawrence is using celiac plexus radiotherapy in a clinical trials to target a source of pain for pancreatic cancer patients.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Progress in BRCA-Related Cancers Highlighted By the Basser Center
The Basser Center for BRCA hosted a panel discussion of the latest breakthroughs and discoveries for BRCA-related cancers.
Using Ultrasound to Enhance the Effectiveness of Chemotherapy
A clinical trial combines ultrasound with a microbubble contrast agent to make chemotherapy more effective.